BCM
NRIX icon

Boxer Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Boxer Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Hold
100,000
– – 0.2% 48
2025
Q4 		$1.9M Sell
100,000
-75,000
-43% -$1.08M 0.42% 36
2025
Q3 		$1.62M Hold
175,000
– – 0.52% 26
2025
Q2 		$1.99M Sell
175,000
-388,067
-69% -$4.19M 1% 15
2025
Q1 		$6.69M Hold
563,067
– – 2.01% 18
2024
Q4 		$10.6M Buy
+563,067
New +$12.9M 0.9% 31

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Boxer Capital Management's NRIX Position: Q1 2026 in Review

Boxer Capital Management held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 100,000 shares worth $1.55M. The position accounts for 0.2% of the portfolio, ranked #48.

Boxer Capital Management first reported a position in NRIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.6M in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Boxer Capital Management held 100,000 shares of Nurix Therapeutics worth $1.55M as of Q1 2026.
  • Boxer Capital Management left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up 0.2% of Boxer Capital Management's portfolio in Q1 2026, its #48 holding.
  • Boxer Capital Management first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Boxer Capital Management's Nurix Therapeutics position peaked at $10.6M in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Boxer Capital Management's 13F filing for Q1 2026, filed 15 May 2026.